- Policy
- Rep. Young-hee Choi ‘expenses surged after Moon Care’
- by Lee, Tak-Sun Oct 18, 2023 05:49am
- After the implementation of Moon Jae-in Care, which was implemented to strengthen health insurance coverage, KRW 5.272 trillion was found to have been spent on drugs for seriously ill patients over the 6 years and exceeded the expenditure target every year. According to data Rep. Choi Young-hee (People Power Party, proportional representa
- Company
- Drug exports reduced by 14%... COVID-19 effect vanished
- by Kim, Jin-Gu Oct 18, 2023 05:48am
- Cumulative pharmaceutical exports in Q3 this year have fallen 13.8% YoY to a record KRW 5.8 trillion. With the global transition to a COVID-19 endemic, exports of COVID-19 vaccines fell sharply, leading to a decline in exports. According to the Korea Customs Service on the 17th, the cumulative pharmaceutical exports in Q3 this year amounted t
- Policy
- Layla+Celecoxib coming soon
- by Lee, Tak-Sun Oct 18, 2023 05:48am
- A compound that combines different osteoarthritis treatments based on natural products and synthesis is expected to be released on the 1st of next month. 20 companies are selling their products, and it is noteworthy whether it will create a new wind in the osteoarthritis treatment market. The original drug ingredient of Danggui, Mogwa, Bangp
- Policy
- Pharma-Bio Control Tower launched…first meeting next month
- by Lee, Jeong-Hwan Oct 18, 2023 05:48am
- A presidential order to establish the Biohealth Innovation Committee, a control tower to foster the pharmaceutical bio-industry, has been issued. The government plans to hold its first meeting next month to begin discussing major agendas. With the launch of a pan-ministerial organization, financial and administrative support is expected to be
- Company
- Controversy arises over illegal rebates made by Company A
- by Nho, Byung Chul Oct 17, 2023 05:28am
- The multinational pharmaceutical company A's illegal rebate activities have gone too far and are disrupting competition in relevant markets. According to an anonymous tip on the 15th, Company A has been providing economic benefits to prescribers at large general hospitals to promote drug sales. The same company was investigated by th
- Policy
- Daewoong's new diabetes drug 'Envlo',
- by Lee, Tak-Sun Oct 17, 2023 05:28am
- Envlo, a new diabetes drug developed by Daewoong Pharmaceutical, is entering long-term safety and efficacy testing of the Zemiglo three-drug therapy. While triple therapy of the Metformin+SGLT2i+DPP4i has been approved for reimbursement since last April, Daewoong Pharmaceutical is expected to establish its position as a latecomer, Envlo, in
- Company
- 'Verquvo is effective in high-risk heart failure patients'
- by Son, Hyung-Min Oct 17, 2023 05:28am
- Bayer’s new heart failure drug Verquvo (vericiguat) has been granted reimbursement listing in Korea, showing effect in high-risk patients. Based on the positive clinical results, experts have been claiming that Verquvo should be considered as a second-line treatment option. On the 16th, Bayer Korea held a press conference celebrating t
- Company
- Xtandi closes coinsurance gap with Erleada
- by Eo, Yun-Ho Oct 17, 2023 05:27am
- 'Xtandi' has virtually overcome its difference in drug price with ‘Erleada.’ Dailpharm’s coverage found out that Astellas Pharma Korea recently reached a final agreement with the National Health Insurance Service to negotiate the drug price for its prostate cancer treatment drug Xtandi (enzalutamide) to convert its indication for metas
- Policy
- Yuhan’s Leclaza passes DREC review for 1st-line NSCLC
- by Lee, Tak-Sun Oct 16, 2023 05:24am
- Yuhan Corp’s application to extend coverage for its 3rd-generation EGFR TKI non-small-cell lung cancer treatment Leclaza (lasertinib)' as a first-line treatment is making rapid progress. After passing the Health Insurance Review and Assessment Service review, all that remains is drug price negotiations with the National Health Insurance
- Company
- Kwangdong and Moderna strengthen partnership
- by Nho, Byung Chul Oct 16, 2023 05:24am
- Kwangdong Pharmaceutical (CEO Choi Seong-won) announced on the 13th that it will begin full-scale activities to provide medical information to medical staff about Moderna's newly updated COVID-19 vaccine 'Spikevax X', which was recently approved by the Ministry of Food and Drug Safety. Moderna's monovalent vaccine against the XBB.1.5 mutat
